Amsterdam UMC, Department of Neurology, Amsterdam Neuroscience, Meibergdreef, University of Amsterdam, Amsterdam, the Netherlands.
Amsterdam UMC, Department of Pediatrics, Amsterdam Neuroscience, Meibergdreef, University of Amsterdam, Amsterdam, the Netherlands.
Clin Microbiol Infect. 2023 Mar;29(3):360-365. doi: 10.1016/j.cmi.2022.10.001. Epub 2022 Oct 8.
We aimed to derive and validate a risk score to differentiate patients with bacterial meningitis from those with viral meningitis or encephalitis amongst patients presenting with cerebrospinal fluid (CSF) leucocytosis and a negative Gram staining result.
We included adults with bacterial and viral meningitis or encephalitis presenting with CSF leukocyte counts of >10 per mm and a negative Gram staining result from cohorts in Houston, Texas (2004-2019), and the Netherlands (2012-2021). Derivation and the first validation were performed in the American patients and further validation in the Dutch patients.
Derivation was performed in 109 American patients with bacterial meningitis (median age, 56 years; interquartile range [IQR], 46-66 years; 46% women) and 194 with viral meningitis or encephalitis (median age, 46 years; IQR, 33-60 years; 53% women). Serum leukocyte counts of >10.0 × 10/L, CSF leukocyte counts of >2000 per mm, granulocyte counts of >1180 per mm, protein levels of >2.2 g/L, glucose levels of <1.9 mmol/L and fever on admission were included in the risk score, which was dichotomized into 'low risk' (0 present) and 'high risk' (>0 present). The first validation showed a sensitivity of 100% (95% CI, 96.6-100) and specificity of 34.0% (95% CI, 27.4-41.2). Further validation in 262 Dutch patients with bacterial meningitis (median age, 57 years; IQR 44-70 years; 45% women) and 68 with viral meningitis (median age, 34 years; IQR, 28-45 years; 60% women) showed a sensitivity of 99.6% (95% CI, 97.9-100) and specificity of 41.2% (95% CI, 29.4-53.7).
Our risk score may be able to rule out bacterial meningitis amongst patients presenting with CSF leucocytosis and a negative Gram staining result. However, it needs prospective testing prior to clinical implementation.
我们旨在建立并验证一个评分系统,以区分以腰椎穿刺(CSF)白细胞计数升高和革兰氏染色阴性为表现的患者中细菌性脑膜炎、病毒性脑膜炎或脑炎患者。
我们纳入了来自美国德克萨斯州休斯顿(2004-2019 年)和荷兰(2012-2021 年)队列的以 CSF 白细胞计数>10/mm³和革兰氏染色阴性为表现的细菌性和病毒性脑膜炎或脑炎患者,对其进行了研究。首先在美国患者中进行推导和验证,然后在荷兰患者中进行进一步验证。
推导在 109 例细菌性脑膜炎(中位年龄 56 岁,四分位间距 [IQR] 46-66 岁,46%为女性)和 194 例病毒性脑膜炎或脑炎(中位年龄 46 岁,IQR 33-60 岁,53%为女性)患者中进行。评分系统纳入了血清白细胞计数>10.0×10/L、CSF 白细胞计数>2000/mm³、粒细胞计数>1180/mm³、蛋白水平>2.2 g/L、血糖水平<1.9 mmol/L 和入院时发热,将其分为“低危”(0 项阳性)和“高危”(>0 项阳性)。首次验证的敏感性为 100%(95%CI,96.6-100),特异性为 34.0%(95%CI,27.4-41.2)。在 262 例细菌性脑膜炎(中位年龄 57 岁,IQR 44-70 岁,45%为女性)和 68 例病毒性脑膜炎(中位年龄 34 岁,IQR 28-45 岁,60%为女性)患者中进行的进一步验证显示敏感性为 99.6%(95%CI,97.9-100),特异性为 41.2%(95%CI,29.4-53.7)。
我们的评分系统可以排除以 CSF 白细胞计数升高和革兰氏染色阴性为表现的患者中细菌性脑膜炎的可能。然而,在临床应用之前,还需要前瞻性测试。